Innodem to Advance Way of Diagnosing, Tracking MS via Eye Movement

Innodem to Advance Way of Diagnosing, Tracking MS via Eye Movement

284269

Innodem to Advance Way of Diagnosing, Tracking MS via Eye Movement

Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring neurodegenerative diseases. The technology is now being tested in people with multiple sclerosis (MS). Money raised by the Montreal-based startup came through a series A financing round led by Morningside Ventures. “Morningside is the ideal investor to help us transition our novel technology into a future industry standard,” Marc Reeves, Innodem’s co-founder and chief business officer, said in a…

You must be logged in to read/download the full post.